Research programme: radiolabelled edotreotide - Progenics Pharmaceuticals

Drug Profile

Research programme: radiolabelled edotreotide - Progenics Pharmaceuticals

Alternative Names: DOTA-Tyr3-octreotide - Progenics Pharmaceuticals; Edotreotide - Progenics Pharmaceuticals; Radiolabelled DOTA-TOC - Progenics Pharmaceuticals

Latest Information Update: 02 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer itm Group; Progenics Pharmaceuticals
  • Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Neuroendocrine tumours

Most Recent Events

  • 18 Sep 2013 Edotreotide and certain radiolabelled edotreotide products sublicensed to itm Group worldwide (excluding Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab Emirates)
  • 18 Sep 2013 Investigation in Neuroendocrine tumours in Germany (IV)
  • 18 Sep 2013 Investigation in Neuroendocrine tumours in USA (IV) with Progenics Pharmaceuticals before Sep 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top